Treatment satisfaction, symptom control and quality of life (QoL) with Lanreotide Autogel (LAN) in NET patients with carcinoid syndrome (CS): results from the SYMNET study.
Authors
Ruszniewski, PCaplin, M
Valle, Juan W
Lombard-Bohas, C
Poston, G
Perros, P
Holubec, L
Delle, F
Smith, D
Niccoli, P
Maisonobe, P
Atlan, P
Affiliation
Beaujon Hospital, Clichy, FranceIssue Date
2015